Companies
YolTech Pharmaceuticals
a Shanghai in-vivo gene-editing company founded in 2021, building AAV-delivered base-editor platforms for cardiovascular and metabolic targets, backed by a more than 300 million yuan B round led by the AstraZeneca-CICC healthcare fund.
- Country
- China
Pilot
AAV-delivered in-vivo base editing, >300M yuan B round (AZ-CICC fund)
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $156 million cumulative funding as of May 2026 | endpoints.news · yoltx.com |
| Production site | GMP-compliant manufacturing facility in Nanjing, China | yoltx.com |
| Capacity | 54,000 square feet after expansion | yoltx.com |
| Regulatory approval | Multiple FDA and NMPA clinical trial clearances and designations for programs including YOLT-101, YOLT-201, YOLT-202, and YOLT-203 | crisprmedicinenews.com · yoltx.com |
| Revenue | Generated through R&D licensing agreements, including a $2 billion potential deal with Serapha and 1.035 billion yuan potential deal with Shenzhen Salubris Pharmaceuticals medium confidence | preqin.com |
Independent sources: crisprmedicinenews.com · endpoints.news · preqin.com · yoltx.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| In-vivo gene therapy: AAV and lentiviral vectors | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.